These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

238 related items for PubMed ID: 12001122

  • 1. Clinical significance of telomerase activity in multiple myeloma.
    Shiratsuchi M, Muta K, Abe Y, Motomura S, Taguchi F, Takatsuki H, Uike N, Umemura T, Nawata H, Nishimura J.
    Cancer; 2002 Apr 15; 94(8):2232-8. PubMed ID: 12001122
    [Abstract] [Full Text] [Related]

  • 2. [Prognostic analysis and assessment on the clinical staging systems of multiple myeloma--a report of 206 cases].
    Tao ZF, Fu WJ, Chen YB, Yuan ZG, Wang DX, Hou J.
    Ai Zheng; 2006 Apr 15; 25(4):461-4. PubMed ID: 16613681
    [Abstract] [Full Text] [Related]

  • 3. Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR.
    Poremba C, Heine B, Diallo R, Heinecke A, Wai D, Schaefer KL, Braun Y, Schuck A, Lanvers C, Bànkfalvi A, Kneif S, Torhorst J, Zuber M, Köchli OR, Mross F, Dieterich H, Sauter G, Stein H, Fogt F, Boecker W.
    J Pathol; 2002 Oct 15; 198(2):181-9. PubMed ID: 12237877
    [Abstract] [Full Text] [Related]

  • 4. High telomerase activity is associated with cell cycle deregulation and rapid progression in endometrioid adenocarcinoma of the uterus.
    Bonatz G, Frahm SO, Klapper W, Helfenstein A, Heidorn K, Jonat W, Krupp G, Parwaresch R, Rudolph P.
    Hum Pathol; 2001 Jun 15; 32(6):605-14. PubMed ID: 11431715
    [Abstract] [Full Text] [Related]

  • 5. [Expression and clinical significance of beta-catenin in multiple myeloma].
    Li J, Zhang DB, Luo SK, Zhao Y, Huang BH, Gu JL.
    Ai Zheng; 2007 Sep 15; 26(9):1010-4. PubMed ID: 17927863
    [Abstract] [Full Text] [Related]

  • 6. Staging multiple myeloma patients with active disease using serum levels of beta2m-free HLA class I heavy chain together with IgM or platelet count.
    Perosa F, Minoia C, Favoino E, Prete M, Dammacco F.
    Blood Cells Mol Dis; 2009 Sep 15; 42(1):71-6. PubMed ID: 18996035
    [Abstract] [Full Text] [Related]

  • 7. A review of the cytokine network in multiple myeloma: diagnostic, prognostic, and therapeutic implications.
    Lauta VM.
    Cancer; 2003 May 15; 97(10):2440-52. PubMed ID: 12733143
    [Abstract] [Full Text] [Related]

  • 8. Prognostic factors and staging systems of multiple myeloma:
    Tao ZF, Fu WJ, Yuan ZG, Wang DX, Chen YB, Hou J.
    Chin Med J (Engl); 2007 Oct 05; 120(19):1655-8. PubMed ID: 17935664
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Analysis of the international staging system of multiple myeloma and its comparison with the DS and IFM staging system in 122 Chinese patients].
    Deng SH, Xu Y, Mai YJ, Wang YF, Zhao YZ, Zou DH, Qiu LG.
    Zhonghua Xue Ye Xue Za Zhi; 2008 Apr 05; 29(4):217-21. PubMed ID: 18843972
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Time to first disease progression, but not beta2-microglobulin, predicts outcome in myeloma patients who receive thalidomide as salvage therapy.
    Palumbo A, Bringhen S, Falco P, Cavallo F, Ambrosini MT, Avonto I, Gay F, Caravita T, Bruno B, Boccadoro M.
    Cancer; 2007 Aug 15; 110(4):824-9. PubMed ID: 17594696
    [Abstract] [Full Text] [Related]

  • 14. [Contribution to the evaluation of the relationship between angiogenic cytokines, selected biological parameters and prognostic factors in multiple myeloma].
    Scudla V, Pika T, Budíková M, Ordeltová M, Minarík J, Zemanová M, Bacovský J, Srovnalík K, Ceská myelomová skupina.
    Cas Lek Cesk; 2006 Aug 15; 145(12):929-35. PubMed ID: 17323615
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Classification and prognostic evaluation in multiple myeloma. A retrospective study of relationship of survivals and responses to chemotherapy to immunological types, 20 single prognostic factors, 15 clinical staging systems, and 6 morphological classifications.
    Pasqualetti P, Colantonio D, Collacciani A, Casale R, Natali G.
    Panminerva Med; 1991 Aug 15; 33(2):93-110. PubMed ID: 1923560
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Correlation of rhodamine 123 efflux by neoplastic plasma cells with clinical and biological characteristics of multiple myeloma.
    Pérez-Simón JA, Valverde B, Martínez A, Tabernero D, Almeida J, Gutierrez N, San Miguel JF, Orfao A.
    Cytometry; 1999 Feb 15; 38(1):24-9. PubMed ID: 10088973
    [Abstract] [Full Text] [Related]

  • 20. Circulating angiogenic cytokines in multiple myeloma and related disorders.
    Urba ska-Rys H, Wierzbowska A, Robak T.
    Eur Cytokine Netw; 2003 Feb 15; 14(1):40-51. PubMed ID: 12799213
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.